Structure via PubChem · Public domain (PubChem)
exemestane
Sign in to saveAlso known as 6-methyleneandrosta-1,4-diene-3,17-dione
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461098446
- Drug.IUPAC_name
- 6-Methylideneandrosta-1,4-diene-3,17-dione
- Drug.image
- Exemestane.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 225
- Drug.image2
- Exemestano.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 225
- Drug.tradename
- Aromasin
- Drug.MedlinePlus
- a607006
- Drug.routes_of_administration
- By mouth
- Drug.class
- Aromatase inhibitor; Antiestrogen
- Drug.ATC_prefix
- L02
- Drug.ATC_suffix
- BG06
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx only
via Wikipedia infobox
Chemical data
- Formula
- C20H24O2
- Molecular weight
- 296.4 g/mol
- IUPAC name
- (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
- SMILES
- C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C
- InChIKey
- BFYIZQONLCFLEV-DAELLWKTSA-N
- XLogP
- 3.1
- Polar surface area
- 34.1 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Research
1,865 papers- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Exemestane.Drugs · 1999
- Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.Advances in therapy · 2022
- Exemestane (FCE 24304), a new steroidal aromatase inhibitor.The Journal of steroid biochemistry and molecular biology · 1992
- Exemestane: a novel aromatase inactivator for breast cancer.Clinical breast cancer · 2000
via PubMed
Wikidata facts
- Mass
- 296.178
Show 7 more facts
- chemical formula
- C₂₀H₂₄O₂
- defined daily dose
- 25
- canonical SMILES
- CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C
- isomeric SMILES
- C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C
- MCN code
- 3003.39.95
- World Health Organisation international non-proprietary name
- exemestane
- Commons category
- Exemestane
via Wikidata · CC0
~9 min read
Article
14 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Overdose
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- Society and culture
- Performance enhancement
- Research
- References
- External links
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.
==Medical uses== Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy. US FDA approval was in October 1999.